REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.

ABSTRACT:

Introduction

A new treatment for coronavirus disease (COVID-19), REGN-COV2, a cocktail consisting of two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been approved for patients at a risk of developing more severe disease.

Methods

We retrospectively reviewed patients recently diagnosed with COVID-19 with risk factors for severe infection, who were treated with the REGN-COV2 antibody cocktail between July and September 2021. The REGN-COV2 antibody cocktail was administered to patients within 7 days of disease onset, with an oxygen saturation of >93%, and with at least one comorbidity. We investigated the percentage of patients with COVID-19-related hospitalization or death, the duration of symptoms after treatment, and the a

SUBMITTER: Sakurai A 

PROVIDER: S-EPMC8986486 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature